Litigation Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2016)

Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2016)

Docket		Date Filed	2016-01-15
Court	District Court, N.D. Illinois	Date Terminated	2018-12-17
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Parties	FRESENIUS KABI USA, LLC
Patents	6,716,867; 8,242,158; 8,338,470; 8,455,527; 8,648,106; 9,320,712; 9,616,049
Attorneys	Tara Lauren Kurtis
Firms	Schiff Hardin LLP
Link to Docket	External link to docket

Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-01-15				External link to document
2016-01-14	1		infringement of U.S. Patent Nos. 8,242,158 (the “‘158 patent”) (Ex. A); 8,338,470 (the “‘470 patent”) (Ex. B); … COUNT I FOR INFRINGEMENT OF PATENT NO. 8,242,158 22. Paragraphs 1 through… claims of the ‘158 patent, the ‘470 patent, the ‘527 patent, and the ‘106 patent are invalid and/or … “‘527 patent”) (Ex. C); and 8,648,106 (the “‘106 patent”) (Ex. D) (collectively, the “Patents-in-suit… THE PATENTS-IN-SUIT 9. The ‘158 patent, entitled “Dexmedetomidine	External link to document
2016-01-14	176	Order on Motion for Leave to File	obtained four patents covering a new product made from dexmedetomidine: U.S. Patent Nos. 8,242,158 (the “’158…’158 Patent”), 8,338,470 (the “’470 Patent”), 8,455,527 (the “’527 Patent”), and 8,648,106 (the “’106…product—U.S. Patent No. 9,616,049 (the “’049 Patent”)—and filed a second complaint of patent infringement…obtained a patent that disclosed and claimed the compound: U.S. Patent No. 4,910,214 (the “’214 Patent”), JTX…named co- inventors of the patents-in-suit. (See ’106 Patent, JTX 1; ’049 Patent, JTX 2.) Dr. Roychowdhury	External link to document

Hospira v. Fresenius Kabi Patent Litigation: Dexmedetomidine, U.S. Patent 8,648,106, and Generic Entry

Last updated: August 3, 2026

Hospira, Inc. sued Fresenius Kabi USA LLC in the District of Delaware after Fresenius submitted an abbreviated new drug application seeking approval for a generic version of Hospira’s ready-to-use Precedex dexmedetomidine formulation. The case, No. 1:16-cv-00651, centered on U.S. Patent No. 8,648,106, which covered a premixed dexmedetomidine hydrochloride formulation.

The District of Delaware initially upheld the asserted patent against Fresenius’s obviousness challenge and found infringement. The Federal Circuit reversed in 2020, holding the asserted claims obvious. The appellate decision removed the principal patent barrier to Fresenius’s ANDA product. The case is therefore a significant generic-entry decision, but not a precedent establishing broad protection for all dexmedetomidine formulations.

What drug and formulation were at issue in Hospira v. Fresenius Kabi?

The litigation concerned dexmedetomidine hydrochloride, the active ingredient in Precedex.

Precedex is an intravenous alpha-2 adrenergic agonist used primarily for sedation in intensive-care and procedural settings. Hospira marketed ready-to-use dexmedetomidine products, including premixed formulations designed to reduce dilution and preparation requirements before administration.

The asserted patent addressed a pharmaceutical composition containing dexmedetomidine hydrochloride in a diluted, ready-to-use formulation. The commercial value of the patent depended on its ability to delay generic competition to Hospira’s premixed Precedex product rather than to block every dexmedetomidine product.

Item	Information
Brand	Precedex
Active ingredient	Dexmedetomidine hydrochloride
Therapeutic class	Alpha-2 adrenergic agonist
Dosage form	Intravenous solution
Plaintiff	Hospira, Inc.
Defendant	Fresenius Kabi USA, LLC
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-00651
Principal patent	U.S. Patent No. 8,648,106
Federal Circuit decision	Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322 (Fed. Cir. 2020)

What patent protected Hospira’s Precedex premixed formulation?

The principal patent was U.S. Patent No. 8,648,106, assigned to Hospira.

The patent covered a ready-to-use dexmedetomidine composition containing dexmedetomidine hydrochloride in a diluted aqueous formulation. The asserted claims were directed to the composition and its characteristics, including the concentration and formulation environment relevant to intravenous administration.

The litigation did not principally concern the basic discovery of dexmedetomidine or the general use of the active ingredient for sedation. It concerned a specific pharmaceutical formulation intended to be supplied without bedside dilution.

U.S. Patent No. 8,648,106

Field	Detail
Patent number	8,648,106
Assignee	Hospira, Inc.
Subject matter	Dexmedetomidine pharmaceutical composition
Commercial relevance	Ready-to-use or premixed intravenous formulation
Asserted against	Fresenius Kabi ANDA product
Litigation result	Asserted claims held obvious by the Federal Circuit
Reported Federal Circuit citation	946 F.3d 1322

The case illustrates the difference between an active-ingredient patent and a formulation patent. Even where the active ingredient is commercially established, a later patent directed to concentration, dilution, packaging, stability, or administration format can create a separate regulatory and litigation barrier.

When did Hospira file the patent lawsuit against Fresenius Kabi?

Hospira filed the action in 2016 after Fresenius submitted an ANDA containing a Paragraph IV certification challenging Hospira’s patent rights.

The filing triggered the Hatch-Waxman litigation framework. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing a patent-infringement action within the statutory period generally creates a 30-month stay of FDA approval, subject to statutory exceptions and later court developments. See 21 U.S.C. § 355(j)(5)(B)(iii).

Litigation timeline

Date	Event
2016	Hospira filed suit in the District of Delaware
2016-2018	Claim-construction, discovery, and validity proceedings
2018	District court entered judgment favorable to Hospira on the asserted patent claims
2020	Federal Circuit issued its decision in 946 F.3d 1322
2020	Federal Circuit held the asserted claims obvious, eliminating the judgment based on patent validity

The case was a patent litigation action under the Hatch-Waxman Act, not a biosimilar proceeding under the Public Health Service Act.

What did Fresenius Kabi argue in its Paragraph IV challenge?

Fresenius challenged the patent primarily on obviousness grounds. Its position was that the claimed ready-to-use dexmedetomidine formulation would have been obvious to a person skilled in the pharmaceutical field based on the existing dexmedetomidine literature, known intravenous formulations, and routine formulation-development practices.

The core issue was whether the prior art provided both:

1. A reason to formulate dexmedetomidine in the claimed ready-to-use concentration and solution; and
2. A reasonable expectation that the resulting formulation would be suitable for commercial intravenous use.

Fresenius also disputed infringement. The Federal Circuit decision, however, is principally significant for its treatment of obviousness. The appellate court concluded that the asserted claims were obvious based on the prior art and the predictable nature of the formulation choices.

Why did the Federal Circuit find Hospira’s patent claims obvious?

The Federal Circuit reversed the district court’s validity determination. The appellate court concluded that the trial court had applied an overly restrictive analysis to motivation to combine and reasonable expectation of success.

The Federal Circuit’s reasoning focused on the following points:

• Dexmedetomidine was already known as an intravenous sedative.
• The prior art disclosed dexmedetomidine formulations and intravenous administration.
• Preparing a diluted, ready-to-use formulation was within the ordinary skill of pharmaceutical formulators.
• The prior art supplied a sufficient reason to pursue the claimed formulation.
• The formulation process did not require an inventive technical leap of the type needed to sustain the patent against an obviousness challenge.

The decision did not hold that every dexmedetomidine formulation was obvious. It held that the particular claims asserted against Fresenius were obvious on the record developed in the case.

Federal Circuit holding

In Hospira, Inc. v. Fresenius Kabi USA, LLC, the Federal Circuit reversed the district court’s judgment upholding the validity of the asserted claims of the ’106 patent. The court determined that the claims were obvious under 35 U.S.C. § 103. Hospira, 946 F.3d at 1322.

The ruling demonstrates that formulation patents can be vulnerable when the claimed parameters are selected from known clinical concentrations, conventional excipients, and established administration practices without evidence of unexpected results.

What was the final litigation outcome?

The final appellate outcome favored Fresenius Kabi on patent validity.

The District of Delaware had entered judgment supporting Hospira’s patent position. The Federal Circuit reversed that result after finding the asserted claims obvious. As a result, the ’106 patent could not continue to block Fresenius’s proposed generic product based on the claims at issue.

The Federal Circuit decision was the controlling merits resolution identified in the published appellate record. It materially weakened Hospira’s ability to rely on the ’106 patent as a barrier to Fresenius’s dexmedetomidine formulation.

What was the Orange Book status of the Hospira patent?

The ’106 patent was associated with Hospira’s dexmedetomidine formulation product and was litigated through an ANDA Paragraph IV challenge. The Orange Book listing was commercially important because it connected the patent to FDA approval of the relevant reference product and enabled the Hatch-Waxman litigation mechanism.

Orange Book status should be separated into three questions:

1. Whether the patent was listed for the reference product.
2. Whether the patent remained within its patent term.
3. Whether the patent could support a valid infringement claim against the proposed ANDA product.

The third question became decisive. Even if a patent remains listed and unexpired, a finding of invalidity removes its practical ability to prevent approval or marketing based on that patent.

The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is the relevant regulatory source for listed patents and exclusivity information. The Federal Circuit’s obviousness decision governs the litigation outcome, not the administrative listing itself. (U.S. Food and Drug Administration, 2024a).

Did Hospira have other patents covering Precedex?

Precedex and dexmedetomidine products have been associated with multiple patent and regulatory rights over time, including patents directed to the active ingredient, formulations, methods of use, and product presentation.

The Fresenius case should not be read as resolving every Hospira patent covering dexmedetomidine. Its direct holding concerned the asserted claims of the ’106 patent. Other listed patents, if any, would require separate analysis of:

• Claim scope;
• Expiration and patent-term adjustment;
• Orange Book listing status;
• The precise ANDA formulation;
• Infringement under the product-by-process or composition limitations;
• Regulatory exclusivity and approval timing.

A patent directed to a method of sedation may present a different risk profile from a composition patent. A patent directed to a vial, bag, concentration, or stability profile may also protect a narrower commercial product than a patent covering the active ingredient itself.

Did the case involve biosimilar risk?

No. Fresenius’s product was a generic drug product submitted under an ANDA, not a biosimilar submitted under the Biologics Price Competition and Innovation Act.

The relevant legal framework was:

• ANDA approval;
• Paragraph IV certification;
• Patent-listing litigation;
• The statutory FDA approval stay;
• Generic drug infringement and validity rules.

Dexmedetomidine hydrochloride is a small-molecule drug. Biosimilar concepts such as reference-product exclusivity under the Public Health Service Act, patent dance procedures, and interchangeable biologic designation were not central to this case.

How strong was Hospira’s patent estate after the Federal Circuit decision?

The ’106 patent was materially weakened as a litigation asset after the Federal Circuit’s obviousness ruling.

Risk category	Assessment
Active-ingredient protection	Not established by this decision
Ready-to-use formulation protection	Substantially weakened for the asserted claims
Obviousness resilience	Low for the claims reviewed by the Federal Circuit
ANDA litigation value	Reduced after appellate reversal
Biosimilar relevance	None
Method-of-use protection	Not resolved by this case
Manufacturing-process protection	Not resolved by this case
Geographic reach	U.S. patent rights only

The decision also carries a broader portfolio lesson. Formulation claims based on conventional dilution, known concentrations, or routine packaging need strong evidence of unexpected stability, safety, compatibility, or clinical performance. Without that evidence, an ANDA challenger can frame the claimed formulation as routine optimization.

What generic-entry risks existed for Precedex?

The main generic-entry risk was the loss of the ’106 patent as a blocking right against Fresenius.

After the Federal Circuit’s decision, the commercial timing of generic entry depended on factors beyond the patent ruling, including:

• FDA review and approval of Fresenius’s ANDA;
• Any remaining Orange Book patents;
• Regulatory exclusivity;
• Manufacturing readiness;
• Commercial launch strategy;
• State substitution and hospital purchasing contracts;
• The scope of the approved generic labeling.

The decision did not automatically establish the precise date of commercial launch. It removed a key patent obstacle. Generic entry could still be delayed by other listed patents, regulatory requirements, settlement terms, or business decisions.

Did Hospira and Fresenius Kabi enter a settlement agreement?

The published Federal Circuit decision does not establish a settlement agreement that resolved the merits of the ’106 patent dispute before appellate judgment.

A settlement would require separate confirmation from a publicly filed agreement, consent judgment, Securities and Exchange Commission filing, or FTC agreement filing. The operative merits record for this case is the Federal Circuit’s decision holding the asserted claims obvious.

What are the licensing and manufacturing implications?

The case did not establish a public license between Hospira and Fresenius Kabi. Its principal commercial effect was on patent leverage rather than licensing economics.

For injectable dexmedetomidine products, manufacturing barriers can remain relevant even after patent invalidation. A generic manufacturer must still demonstrate:

• Sterility assurance;
• Container-closure integrity;
• Stability over the proposed shelf life;
• Compatibility with the container and delivery system;
• Appropriate concentration and labeling;
• Compliance with current good manufacturing practice requirements.

Those requirements are regulatory and operational barriers, not substitutes for valid patent rights. They can affect launch timing and cost, but they do not preserve an invalid patent.

How does this case compare with ordinary formulation-patent litigation?

Hospira v. Fresenius Kabi is a conventional Hatch-Waxman formulation case with an important appellate validity ruling.

Its principal distinctions are:

• The active ingredient was established before the asserted formulation patent.
• The dispute focused on a ready-to-use injectable composition.
• The prior art supplied substantial information regarding dexmedetomidine use and formulation.
• The Federal Circuit rejected a narrow view of motivation to combine.
• The appellate decision converted a district-court victory for the brand company into a generic-side validity victory.

The case is most relevant to pharmaceutical companies evaluating late-stage formulation patents, particularly claims based on concentration, dilution, excipient selection, or ready-to-use presentation.

Key Takeaways

• Hospira sued Fresenius Kabi in 2016 over a generic dexmedetomidine formulation.
• The principal patent was U.S. Patent No. 8,648,106.
• The case involved an ANDA and Paragraph IV certification, not a biosimilar application.
• The District of Delaware initially ruled in Hospira’s favor.
• The Federal Circuit reversed and held the asserted claims obvious.
• The decision substantially reduced the ’106 patent’s value as a barrier to generic Precedex entry.
• The ruling did not invalidate every patent covering dexmedetomidine or resolve every possible method-of-use, manufacturing, or formulation claim.
• The case is a leading example of a ready-to-use injectable formulation patent failing under an obviousness challenge.

FAQs About Hospira v. Fresenius Kabi

What product did Fresenius Kabi seek to market?

Fresenius sought FDA approval for a generic dexmedetomidine hydrochloride intravenous formulation corresponding to Hospira’s Precedex product.

Which patent did Hospira assert?

Hospira principally asserted U.S. Patent No. 8,648,106, directed to a dexmedetomidine pharmaceutical composition.

What legal doctrine decided the appeal?

The Federal Circuit decided the appeal under the obviousness standard in 35 U.S.C. § 103.

Did the Federal Circuit rule that dexmedetomidine itself was unpatentable?

No. The decision addressed the asserted claims of the ’106 formulation patent. It did not establish that every patent claim directed to dexmedetomidine or its clinical use was invalid.

What is the business significance for injectable-drug developers?

The case shows that ready-to-use injectable formulation claims require a strong technical record, including unexpected stability, compatibility, safety, or clinical advantages when the active ingredient and general administration route are already known.

References

1. Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322 (Fed. Cir. 2020).

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024b). Abbreviated new drug application regulations and patent certifications. U.S. Department of Health and Human Services.

4. 21 U.S.C. § 355(j).

5. 35 U.S.C. § 103.